Araştırma Makalesi
BibTex RIS Kaynak Göster

Intravenous immunoglobulin treatment and evaluation of autoinflammatory and immunodeficiency-associated recurrent parotitis cases in children

Yıl 2025, Cilt: 42 Sayı: 1, 58 - 62, 28.03.2025

Şefika İlknur Kökçü Karadağ , Ömer Salih Akar , Engin Altundağ , Alişan Yıldıran

Öz

Abstract:
Recurrent juvenile parotitis is a rare inflammatory condition characterized by recurrent, non-obstructive, and non-suppurative inflammation of the parotid gland during childhood. Diagnosis of the disease is based on clinical symptoms and laboratory tests. Although cases of recurrent parotitis are rare, various diseases can contribute to its etiology. Case series in the literature have reported diagnoses of immunodeficiency and autoimmune diseases. This study presents five cases diagnosed with autoimmune disease and immunodeficiency, successfully treated with intravenous immunoglobulin.

Anahtar Kelimeler

Recurrent Parotitis Intravenous Immunoglobulin Immunodeficiency

Etik Beyan

This study obtained approval from the local ethics committee of *****Mayıs University (Number 2024/261). Patients' informed consent was obtained. Our study was conducted in accordance with the Helsinki Declaration.

Destekleyen Kurum

This study did not receive any funding.

Kaynakça

  • 1. Okuda S, Kamei S, Sasaki T. Immunoglobulin G Enhances Generation of Inducible T Regulatory Cells and Increases Their Regulatory Function. Biol Pharm Bull. 2018;41(12):1830-1836. doi:10.1248/bpb.b18-00548
  • 2. Hidalgo-Santos AD, Gastón-Téllez R, Ferrer-Lorente B, Pina-Pérez R, Oltra-Benavent M. Immune disorders associated with juvenile recurrent chronic parotitis. An Pediatr (Engl Ed). 2021;95(4):260-266. doi:10.1016/j.anpede.2020.08.012
  • 3. Leerdam CM, Martin HC, Isaacs D. Recurrent parotitis of childhood. J Paediatr Child Health. 2005;41(12):631-634. doi:10.1111/j.1440-1754.2005.00773.x
  • 4. Ericson S, Zetterlund B, Ohman J. Recurrent parotitis and sialectasis in childhood. Clinical, radiologic, immunologic, bacteriologic, and histologic study. Ann Otol Rhinol Laryngol. 1991;100(7):527-535. doi:10.1177/000348949110000702
  • 5. Yıldıran A. Autoinflammatory Diseases and Their Genetic Markers. Turkiye Klinikleri J Pediatr Sci 2016;12(4):16-28
  • 6. Celiksoy MH, Ogur G, Yaman E, et al. Could familial Mediterranean fever gene mutations be related to PFAPA syndrome?. Pediatr Allergy Immunol. 2016;27(1):78-82. doi:10.1111/pai.12490
  • 7. Akar HH, Patıroglu T, Duman L. A selective IgA deficiency in a boy who presented recurrent parotitis. Eur J Microbiol Immunol (Bp). 2014;4(2):144-146. doi:10.1556/EuJMI.4.2014.2.8
  • 8. Wu S, Shi H, Cao N, Ye L, Yu C, Zheng L. The correlation of immunologic derangement and juvenile recurrent parotitis: an investigation of the laboratory immunological observation. Acta Otolaryngol. 2018;138(12):1112-1116. doi:10.1080/00016489.2018.15154989
  • 9. Wood J, Toll EC, Hall F, Mahadevan M. Juvenile recurrent parotitis: Review and proposed management algorithm. Int J Pediatr Otorhinolaryngol. 2021 Mar;142:110617. doi: 10.1016/j.ijporl.2021.110617. Epub 2021 Jan 4. PMID: 33421670.
  • 10. Maddur MS, Othy S, Hegde P, Vani J, Lacroix-Desmazes S, Bayry J, Kaveri SV. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol. 2010 May;30 Suppl 1:S4-8. doi: 10.1007/s10875-010-9394-5. PMID: 20405183.
  • 11. Fonseca R, Gonçalves D, Aguiar F, Abelha-Aleixo J, Madureira P, Vieira R, et al. Intravenous Immunoglobulin (IVIG) is Effective and Safe in Severe or Refractory Rheumatic Diseases. Ann Rheum Dis. 2014 Jun;73(Suppl 2):1109–1110. doi:10.1136/annrheumdis-2014-eular.4592
  • 12. Garcia-Geremias M, Carreño E, Epps SJ, Lee RW, Dick AD. Clinical outcomes of intravenous immunoglobulin therapy in refractory uveitis. Int Ophthalmol. 2015 Apr;35(2):281-5. doi: 10.1007/s10792-015-0051-0. Epub 2015 Feb 24. PMID: 25708281.
  • 13. Wildman SHA, Al‐Obaidi M. P136 – Adverse reaction with intravenous immunoglobulin (IVIG) therapy and management of symptoms: A single centre experience. Rheumatology. 2020;59(Suppl_1). doi:10.1093/rheumatology/keaa111.131
  • 14. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007;6(4):257–259. doi:10.1016/j.autrev.2006.08.011

Yıl 2025, Cilt: 42 Sayı: 1, 58 - 62, 28.03.2025

Şefika İlknur Kökçü Karadağ , Ömer Salih Akar , Engin Altundağ , Alişan Yıldıran

Öz

Kaynakça

  • 1. Okuda S, Kamei S, Sasaki T. Immunoglobulin G Enhances Generation of Inducible T Regulatory Cells and Increases Their Regulatory Function. Biol Pharm Bull. 2018;41(12):1830-1836. doi:10.1248/bpb.b18-00548
  • 2. Hidalgo-Santos AD, Gastón-Téllez R, Ferrer-Lorente B, Pina-Pérez R, Oltra-Benavent M. Immune disorders associated with juvenile recurrent chronic parotitis. An Pediatr (Engl Ed). 2021;95(4):260-266. doi:10.1016/j.anpede.2020.08.012
  • 3. Leerdam CM, Martin HC, Isaacs D. Recurrent parotitis of childhood. J Paediatr Child Health. 2005;41(12):631-634. doi:10.1111/j.1440-1754.2005.00773.x
  • 4. Ericson S, Zetterlund B, Ohman J. Recurrent parotitis and sialectasis in childhood. Clinical, radiologic, immunologic, bacteriologic, and histologic study. Ann Otol Rhinol Laryngol. 1991;100(7):527-535. doi:10.1177/000348949110000702
  • 5. Yıldıran A. Autoinflammatory Diseases and Their Genetic Markers. Turkiye Klinikleri J Pediatr Sci 2016;12(4):16-28
  • 6. Celiksoy MH, Ogur G, Yaman E, et al. Could familial Mediterranean fever gene mutations be related to PFAPA syndrome?. Pediatr Allergy Immunol. 2016;27(1):78-82. doi:10.1111/pai.12490
  • 7. Akar HH, Patıroglu T, Duman L. A selective IgA deficiency in a boy who presented recurrent parotitis. Eur J Microbiol Immunol (Bp). 2014;4(2):144-146. doi:10.1556/EuJMI.4.2014.2.8
  • 8. Wu S, Shi H, Cao N, Ye L, Yu C, Zheng L. The correlation of immunologic derangement and juvenile recurrent parotitis: an investigation of the laboratory immunological observation. Acta Otolaryngol. 2018;138(12):1112-1116. doi:10.1080/00016489.2018.15154989
  • 9. Wood J, Toll EC, Hall F, Mahadevan M. Juvenile recurrent parotitis: Review and proposed management algorithm. Int J Pediatr Otorhinolaryngol. 2021 Mar;142:110617. doi: 10.1016/j.ijporl.2021.110617. Epub 2021 Jan 4. PMID: 33421670.
  • 10. Maddur MS, Othy S, Hegde P, Vani J, Lacroix-Desmazes S, Bayry J, Kaveri SV. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol. 2010 May;30 Suppl 1:S4-8. doi: 10.1007/s10875-010-9394-5. PMID: 20405183.
  • 11. Fonseca R, Gonçalves D, Aguiar F, Abelha-Aleixo J, Madureira P, Vieira R, et al. Intravenous Immunoglobulin (IVIG) is Effective and Safe in Severe or Refractory Rheumatic Diseases. Ann Rheum Dis. 2014 Jun;73(Suppl 2):1109–1110. doi:10.1136/annrheumdis-2014-eular.4592
  • 12. Garcia-Geremias M, Carreño E, Epps SJ, Lee RW, Dick AD. Clinical outcomes of intravenous immunoglobulin therapy in refractory uveitis. Int Ophthalmol. 2015 Apr;35(2):281-5. doi: 10.1007/s10792-015-0051-0. Epub 2015 Feb 24. PMID: 25708281.
  • 13. Wildman SHA, Al‐Obaidi M. P136 – Adverse reaction with intravenous immunoglobulin (IVIG) therapy and management of symptoms: A single centre experience. Rheumatology. 2020;59(Suppl_1). doi:10.1093/rheumatology/keaa111.131
  • 14. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007;6(4):257–259. doi:10.1016/j.autrev.2006.08.011
Toplam 14 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Çocuk İmmünolojisi ve Alerji Hastalıkları
Bölüm Research Article
Yazarlar

Şefika İlknur Kökçü Karadağ 0000-0001-9234-633X

Ömer Salih Akar 0000-0001-5686-2185

Engin Altundağ 0000-0001-8841-1426

Alişan Yıldıran 0000-0002-2918-6238

Yayımlanma Tarihi 28 Mart 2025
Gönderilme Tarihi 9 Eylül 2024
Kabul Tarihi 24 Mart 2025
Yayımlandığı Sayı Yıl 2025 Cilt: 42 Sayı: 1

Kaynak Göster

APA Kökçü Karadağ, Ş. İ., Akar, Ö. S., Altundağ, E., Yıldıran, A. (2025). Intravenous immunoglobulin treatment and evaluation of autoinflammatory and immunodeficiency-associated recurrent parotitis cases in children. Deneysel Ve Klinik Tıp Dergisi, 42(1), 58-62.
AMA Kökçü Karadağ Şİ, Akar ÖS, Altundağ E, Yıldıran A. Intravenous immunoglobulin treatment and evaluation of autoinflammatory and immunodeficiency-associated recurrent parotitis cases in children. J. Exp. Clin. Med. Mart 2025;42(1):58-62.
Chicago Kökçü Karadağ, Şefika İlknur, Ömer Salih Akar, Engin Altundağ, ve Alişan Yıldıran. “Intravenous Immunoglobulin Treatment and Evaluation of Autoinflammatory and Immunodeficiency-Associated Recurrent Parotitis Cases in Children”. Deneysel Ve Klinik Tıp Dergisi 42, sy. 1 (Mart 2025): 58-62.
EndNote Kökçü Karadağ Şİ, Akar ÖS, Altundağ E, Yıldıran A (01 Mart 2025) Intravenous immunoglobulin treatment and evaluation of autoinflammatory and immunodeficiency-associated recurrent parotitis cases in children. Deneysel ve Klinik Tıp Dergisi 42 1 58–62.
IEEE Ş. İ. Kökçü Karadağ, Ö. S. Akar, E. Altundağ, ve A. Yıldıran, “Intravenous immunoglobulin treatment and evaluation of autoinflammatory and immunodeficiency-associated recurrent parotitis cases in children”, J. Exp. Clin. Med., c. 42, sy. 1, ss. 58–62, 2025.
ISNAD Kökçü Karadağ, Şefika İlknur vd. “Intravenous Immunoglobulin Treatment and Evaluation of Autoinflammatory and Immunodeficiency-Associated Recurrent Parotitis Cases in Children”. Deneysel ve Klinik Tıp Dergisi 42/1 (Mart 2025), 58-62.
JAMA Kökçü Karadağ Şİ, Akar ÖS, Altundağ E, Yıldıran A. Intravenous immunoglobulin treatment and evaluation of autoinflammatory and immunodeficiency-associated recurrent parotitis cases in children. J. Exp. Clin. Med. 2025;42:58–62.
MLA Kökçü Karadağ, Şefika İlknur vd. “Intravenous Immunoglobulin Treatment and Evaluation of Autoinflammatory and Immunodeficiency-Associated Recurrent Parotitis Cases in Children”. Deneysel Ve Klinik Tıp Dergisi, c. 42, sy. 1, 2025, ss. 58-62.
Vancouver Kökçü Karadağ Şİ, Akar ÖS, Altundağ E, Yıldıran A. Intravenous immunoglobulin treatment and evaluation of autoinflammatory and immunodeficiency-associated recurrent parotitis cases in children. J. Exp. Clin. Med. 2025;42(1):58-62.
 Kapak Resmi İndir

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.